Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash to Debt No Debt
ENZY's Cash to Debt is ranked higher than
76% of the 941 Companies
in the Global Biotechnology industry.

( Industry Median: 45.46 vs. ENZY: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ENZY' s Cash to Debt Range Over the Past 10 Years
Min: 0.46  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.92
ENZY's Equity to Asset is ranked higher than
89% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ENZY: 0.92 )
Ranked among companies with meaningful Equity to Asset only.
ENZY' s Equity to Asset Range Over the Past 10 Years
Min: 0.67  Med: 0.92 Max: 0.93
Current: 0.92
0.67
0.93
Interest Coverage 13.75
ENZY's Interest Coverage is ranked lower than
79% of the 369 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ENZY: 13.75 )
Ranked among companies with meaningful Interest Coverage only.
ENZY' s Interest Coverage Range Over the Past 10 Years
Min: 8.09  Med: 30.19 Max: 52.46
Current: 13.75
8.09
52.46
F-Score: 8
Z-Score: 9.98
M-Score: -2.78
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 11.07
ENZY's Operating margin (%) is ranked higher than
79% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -75.67 vs. ENZY: 11.07 )
Ranked among companies with meaningful Operating margin (%) only.
ENZY' s Operating margin (%) Range Over the Past 10 Years
Min: -1.51  Med: 14.04 Max: 18.1
Current: 11.07
-1.51
18.1
Net-margin (%) 12.05
ENZY's Net-margin (%) is ranked higher than
82% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -76.14 vs. ENZY: 12.05 )
Ranked among companies with meaningful Net-margin (%) only.
ENZY' s Net-margin (%) Range Over the Past 10 Years
Min: -3.75  Med: 13.26 Max: 17.54
Current: 12.05
-3.75
17.54
ROE (%) 4.73
ENZY's ROE (%) is ranked higher than
80% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -32.22 vs. ENZY: 4.73 )
Ranked among companies with meaningful ROE (%) only.
ENZY' s ROE (%) Range Over the Past 10 Years
Min: -3.14  Med: 6.37 Max: 15.5
Current: 4.73
-3.14
15.5
ROA (%) 4.35
ENZY's ROA (%) is ranked higher than
83% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. ENZY: 4.35 )
Ranked among companies with meaningful ROA (%) only.
ENZY' s ROA (%) Range Over the Past 10 Years
Min: -1.89  Med: 5.71 Max: 12.16
Current: 4.35
-1.89
12.16
ROC (Joel Greenblatt) (%) 11.14
ENZY's ROC (Joel Greenblatt) (%) is ranked higher than
80% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. ENZY: 11.14 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ENZY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -0.51  Med: 13.81 Max: 28.12
Current: 11.14
-0.51
28.12
» ENZY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

ENZY Guru Trades in Q2 2015

Jim Simons 82,494 sh (+52.20%)
John Paulson 4,238,275 sh (unchged)
» More
Q3 2015

ENZY Guru Trades in Q3 2015

Julian Robertson 804,854 sh (New)
Jim Simons 146,000 sh (+76.98%)
John Paulson 4,238,275 sh (unchged)
» More
Q4 2015

ENZY Guru Trades in Q4 2015

Jim Simons 217,700 sh (+49.11%)
Julian Robertson 1,162,845 sh (+44.48%)
John Paulson 4,238,275 sh (unchged)
» More
Q1 2016

ENZY Guru Trades in Q1 2016

John Paulson 4,224,139 sh (-0.33%)
Julian Robertson 1,143,145 sh (-1.69%)
Jim Simons 181,000 sh (-16.86%)
» More
» Details

Insider Trades

Latest Guru Trades with ENZY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:CBMG, NAS:ABUS, NAS:QURE, NAS:FOMX, AMEX:PFNX, AMEX:MDGN, NAS:IDRA, NAS:OSIR, OTCPK:BBLG, NAS:BOLT, NAS:ITEK, NAS:NVIV, NAS:FLKS, NAS:VTVT, NAS:MDWD, OTCPK:SPHRY, NAS:CMRX, AMEX:AMPE, OTCPK:CTIX, NAS:CDXS » details
Traded in other countries:EZ4.Germany,
Enzymotec Ltd develops, manufactures, markets & sells innovative bio-functional lipid ingredients, and final products, based on sophisticated proprietary processes & technologies. The Company's segments include Nutrition Segment & VAYA Pharma Segment.

Top Ranked Articles about Enzymotec Ltd

Tiger Management Founder Julian Robertson Ups Stake in Enzymotec Biotech company is up 25% for the year
Guru Julian Robertson (Trades, Portfolio) is a legendary billionaire investor and founder of Tiger Management, which netted an outstanding average return of 32% from 1980 to 2000. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 28.63
ENZY's P/E(ttm) is ranked higher than
50% of the 230 Companies
in the Global Biotechnology industry.

( Industry Median: 29.12 vs. ENZY: 28.63 )
Ranked among companies with meaningful P/E(ttm) only.
ENZY' s P/E(ttm) Range Over the Past 10 Years
Min: 16.71  Med: 35.05 Max: 146.67
Current: 28.63
16.71
146.67
PE(NRI) 28.63
ENZY's PE(NRI) is ranked higher than
50% of the 230 Companies
in the Global Biotechnology industry.

( Industry Median: 28.93 vs. ENZY: 28.63 )
Ranked among companies with meaningful PE(NRI) only.
ENZY' s PE(NRI) Range Over the Past 10 Years
Min: 9.56  Med: 28.91 Max: 55.87
Current: 28.63
9.56
55.87
P/B 1.30
ENZY's P/B is ranked higher than
84% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. ENZY: 1.30 )
Ranked among companies with meaningful P/B only.
ENZY' s P/B Range Over the Past 10 Years
Min: 1  Med: 1.57 Max: 11.01
Current: 1.3
1
11.01
P/S 3.52
ENZY's P/S is ranked higher than
77% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 10.08 vs. ENZY: 3.52 )
Ranked among companies with meaningful P/S only.
ENZY' s P/S Range Over the Past 10 Years
Min: 1.26  Med: 3.54 Max: 5.88
Current: 3.52
1.26
5.88
PFCF 21.27
ENZY's PFCF is ranked higher than
63% of the 126 Companies
in the Global Biotechnology industry.

( Industry Median: 26.54 vs. ENZY: 21.27 )
Ranked among companies with meaningful PFCF only.
ENZY' s PFCF Range Over the Past 10 Years
Min: 20.64  Med: 40.95 Max: 451.3
Current: 21.27
20.64
451.3
POCF 16.17
ENZY's POCF is ranked higher than
63% of the 183 Companies
in the Global Biotechnology industry.

( Industry Median: 22.98 vs. ENZY: 16.17 )
Ranked among companies with meaningful POCF only.
ENZY' s POCF Range Over the Past 10 Years
Min: 10.93  Med: 20.66 Max: 686.67
Current: 16.17
10.93
686.67
EV-to-EBIT 21.66
ENZY's EV-to-EBIT is ranked higher than
51% of the 248 Companies
in the Global Biotechnology industry.

( Industry Median: 22.57 vs. ENZY: 21.66 )
Ranked among companies with meaningful EV-to-EBIT only.
ENZY' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.2  Med: 22.05 Max: 44.2
Current: 21.66
7.2
44.2
EV-to-EBITDA 15.68
ENZY's EV-to-EBITDA is ranked higher than
56% of the 273 Companies
in the Global Biotechnology industry.

( Industry Median: 19.06 vs. ENZY: 15.68 )
Ranked among companies with meaningful EV-to-EBITDA only.
ENZY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.3  Med: 16.80 Max: 34.9
Current: 15.68
6.3
34.9
Current Ratio 7.25
ENZY's Current Ratio is ranked higher than
67% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. ENZY: 7.25 )
Ranked among companies with meaningful Current Ratio only.
ENZY' s Current Ratio Range Over the Past 10 Years
Min: 2.31  Med: 7.25 Max: 8.76
Current: 7.25
2.31
8.76
Quick Ratio 5.20
ENZY's Quick Ratio is ranked higher than
57% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. ENZY: 5.20 )
Ranked among companies with meaningful Quick Ratio only.
ENZY' s Quick Ratio Range Over the Past 10 Years
Min: 1.5  Med: 5.52 Max: 7.31
Current: 5.2
1.5
7.31
Days Inventory 402.96
ENZY's Days Inventory is ranked lower than
92% of the 449 Companies
in the Global Biotechnology industry.

( Industry Median: 128.00 vs. ENZY: 402.96 )
Ranked among companies with meaningful Days Inventory only.
ENZY' s Days Inventory Range Over the Past 10 Years
Min: 121.07  Med: 169.63 Max: 403.27
Current: 402.96
121.07
403.27
Days Sales Outstanding 90.84
ENZY's Days Sales Outstanding is ranked lower than
69% of the 611 Companies
in the Global Biotechnology industry.

( Industry Median: 63.07 vs. ENZY: 90.84 )
Ranked among companies with meaningful Days Sales Outstanding only.
ENZY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 104.09  Med: 108.33 Max: 120.92
Current: 90.84
104.09
120.92
Days Payable 110.15
ENZY's Days Payable is ranked higher than
69% of the 450 Companies
in the Global Biotechnology industry.

( Industry Median: 59.87 vs. ENZY: 110.15 )
Ranked among companies with meaningful Days Payable only.
ENZY' s Days Payable Range Over the Past 10 Years
Min: 102.78  Med: 107.56 Max: 145.45
Current: 110.15
102.78
145.45

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.12
ENZY's Price/Net Cash is ranked lower than
54% of the 504 Companies
in the Global Biotechnology industry.

( Industry Median: 5.38 vs. ENZY: 6.12 )
Ranked among companies with meaningful Price/Net Cash only.
ENZY' s Price/Net Cash Range Over the Past 10 Years
Min: 5.38  Med: 6.87 Max: 10.39
Current: 6.12
5.38
10.39
Price/Net Current Asset Value 2.63
ENZY's Price/Net Current Asset Value is ranked higher than
76% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 5.07 vs. ENZY: 2.63 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ENZY' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.55  Med: 2.96 Max: 14.91
Current: 2.63
2.55
14.91
Price/Tangible Book 1.30
ENZY's Price/Tangible Book is ranked higher than
88% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 3.99 vs. ENZY: 1.30 )
Ranked among companies with meaningful Price/Tangible Book only.
ENZY' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.18  Med: 1.53 Max: 6.82
Current: 1.3
1.18
6.82
Price/Median PS Value 0.99
ENZY's Price/Median PS Value is ranked lower than
58% of the 633 Companies
in the Global Biotechnology industry.

( Industry Median: 0.91 vs. ENZY: 0.99 )
Ranked among companies with meaningful Price/Median PS Value only.
ENZY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.39  Med: 1.06 Max: 1.28
Current: 0.99
0.39
1.28
Price/Graham Number 1.29
ENZY's Price/Graham Number is ranked higher than
78% of the 185 Companies
in the Global Biotechnology industry.

( Industry Median: 3.09 vs. ENZY: 1.29 )
Ranked among companies with meaningful Price/Graham Number only.
ENZY' s Price/Graham Number Range Over the Past 10 Years
Min: 1.16  Med: 1.45 Max: 1.86
Current: 1.29
1.16
1.86
Earnings Yield (Greenblatt) (%) 4.66
ENZY's Earnings Yield (Greenblatt) (%) is ranked higher than
87% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. ENZY: 4.66 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ENZY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.3  Med: 4.50 Max: 13.9
Current: 4.66
2.3
13.9

More Statistics

Revenue (TTM) (Mil) $53.06
EPS (TTM) $ 0.28
Short Percentage of Float0.29%
52-Week Range $6.60 - 10.70
Shares Outstanding (Mil)22.72

Analyst Estimate

Dec16 Dec17
Revenue (Mil $) 56 65
EPS ($) 0.25 0.50
EPS w/o NRI ($) 0.25 0.50
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for ENZY

Headlines

Articles On GuruFocus.com
Tiger Management Founder Julian Robertson Ups Stake in Enzymotec Dec 07 2015 
What Drives St. Jude Medical to Be More Diversified? Apr 30 2014 

More From Other Websites
2016-05-25 Bulletin from the Annual General Meeting in Enzymatica AB (publ) May 25 2016
Enzymotec Ltd. :ENZY-US: Earnings Analysis: Q1, 2016 By the Numbers : May 23, 2016 May 23 2016
Edited Transcript of ENZY earnings conference call or presentation 19-May-16 12:30pm GMT May 20 2016
Enzymotec Ltd. Reports First Quarter 2016 Unaudited Financial Results May 19 2016
Enzymotec beats 1Q profit forecasts May 19 2016
Enzymotec beats 1Q profit forecasts May 19 2016
Enzymotec Ltd. Reports First Quarter 2016 Unaudited Financial Results May 19 2016
Q1 2016 Enzymotec Ltd Earnings Release - Before Market Open May 19 2016
2016-05-11 Enzymatica's new rights issue completed - will be provided with SEK 60 million May 11 2016
Enzymotec to Report First Quarter 2016 Financial Results May 05 2016
Enzymotec to Report First Quarter 2016 Financial Results May 05 2016
New Survey Shows Nearly 3 Out of 4 Children Treated for ADHD Have Taken a “Drug Holiday” May 04 2016
2016-05-03 Enzymatica insiders plan to subscribe for SEK 16 million in new issue May 03 2016
New Retrospective Study Shows PS-Omega-3 Medical Food Effective in Managing ADHD Apr 26 2016
2016-04-26 Notice of annual general meeting in Enzymatica AB (publ) Apr 26 2016
2016-04-20 Enzymatica publishes prospectus Apr 20 2016
2016-04-20 Enzymatica - publication of the annual report 2015 Apr 20 2016
2016-04-18 Interim Report for Enzymatica AB (publ) January-March 2016 Apr 18 2016
2016-04-01 Enzymatica completes acquisition of Zymetech and includes new board members and... Apr 01 2016
Enzymotec Ltd. Granted Patents in U.S. for Compositions and Processes Related to Infant Nutrition... Mar 29 2016
2016-03-24 Acting CFO of Enzymatica appointed Mar 24 2016
ENZYMOTEC LTD. Financials Mar 09 2016
Enzymotec (ENZY): Moving Average Crossover Alert Mar 08 2016
Edited Transcript of ENZY earnings conference call or presentation 17-Feb-16 1:30pm GMT Feb 22 2016
Enzymotec Ltd. Earnings Analysis: 2015 By the Numbers Feb 22 2016
Enzymotec misses 4Q profit forecasts Feb 17 2016
Enzymotec misses 4Q profit forecasts Feb 17 2016
2016-01-28 NOTICE OF EXTRAORDINARY SHAREHOLDERS' MEETING IN ENZYMATICA AB (PUBL) Jan 28 2016
2016-01-28 Enzymatica signs acquisition agreement and prepares for international expansion with new... Jan 28 2016
Enzymotec Updates Automatic Extension of Its Joint Venture Agreement With AAK Until December 31,... Jan 04 2016
Enzymotec Ltd. Earnings Analysis: Q3, 2015 By the Numbers Dec 23 2015
Hedge Fund Sentiment Is Stagnant On Enzymotec Ltd (ENZY) Dec 09 2015
Appaloosa Management Sends Letter To TerraForm Power & Three Other Notable Hedge Fund Moves Dec 08 2015
Tiger Management Founder Julian Robertson Ups Stake in Enzymotec Dec 07 2015
Why Enzymotec (ENZY) Could Be Positioned for a Surge? Nov 23 2015
2015-11-12 Enzymatica signs distribution agreement with Esteve in Spain Nov 12 2015
Enzymotec Ltd. Reports Third Quarter 2015 Results Nov 11 2015
Enzymotec beats 3Q profit forecasts Nov 11 2015
Enzymotec beats 3Q profit forecasts Nov 11 2015
Enzymotec to Host a VAYA Pharma Analyst and Investor Day in New York City on November 19, 2015 Nov 10 2015
2015-11-10 Enzymatica signs distribution agreement with Tamro for the Finnish market Nov 10 2015
Enzymotec to Report Third Quarter 2015 Financial Results Oct 29 2015
Enzymotec (ENZY) Sees Hammer Chart Pattern: Time to Buy? Oct 07 2015
Enzymotec Ltd. Earnings Q2, 2015 Oct 01 2015
Rockwell Medical (RMTI) Looks Good: Stock Adds 8.5% Sep 30 2015
Enzymotec beats 2Q profit forecasts Aug 12 2015
Enzymotec beats 1Q profit forecasts May 07 2015
Enzymotec posts 4Q profit Feb 18 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)